Gara Jalqabaatti › Kansa Mataa fi Morma › Massachusetts
Qorannoo klinikaalii Kansa Mataa fi Morma Massachusetts keessatti
Qorannoo 24 Kansa Mataa fi Morma f Massachusetts keessatti hirmaatuu jiru.
Magaalota Massachusetts keessatti
Takkalaa qorannoo (Ingiliffa)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04585750FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site #0131, Boston
- Site#0101, Boston
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06788990Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07059884A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT07090499First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT06657222Toripalimab With Chemotherapy for Sinus Cancer
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 31-Hag-2026 · NCT06940180PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT06239220A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT05592626Jump: MR Simulation For Radiation Therapy Master Protocol
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Ado-2026 · NCT04545957PDT For Induction Therapy For Head And Neck Cancer
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ado-2026 · NCT07214987First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Ado-2026 · NCT05768139Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Wax-2026 · NCT07675967Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Wax-2026 · NCT06993844Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Wax-2026 · NCT05726370A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Massachusetts General Hospital,, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 27-Cam-2026 · NCT03093116A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Worcester
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 26-Cam-2026 · NCT06256588Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Cam-2026 · NCT06239194Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT03875716Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
- Brigham and Women's Hospital, Boston
Namoota walitti qabaa jira
Umuriin 18 hanga 85 · Saalaa hunda · Haaromfame 12-Gur-2026 · NCT07405645Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 26-Ama-2026 · NCT05553782SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2025 · NCT05941507Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Dana Farber/Partners Cancer Care Inc, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Hag-2025 · NCT04429542Comprehensive Outcomes for After Cancer Health
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Mud-2024 · NCT05349227Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.